NextGen Group plc, through its subsidiaries, provides research and development services in the biomarker arena for use in the life science companies and academic institutions, as well as develops diagnostic markers. It focuses on oncology and central nervous system disease areas. The company, through multiple reaction monitoring mass spectrometry analysis technology, develops a portfolio of assays for testing clinical samples for drug safety and efficacy, as well as for developing personalized treatment for patients. It offers proteomic services with a focus on protein biomarker discovery, assay development, validation, and testing that enable researchers to characterize and measure proteins in biological samples. The company’s services include the identification and characterization of clinically relevant proteins (putative biomarkers), assay development, qualification, verification and validation of the protein biomarker, and monitoring of protein biomarkers during drug development phases. It has operations primarily in the United States and Europe. NextGen Group plc is based in London, the United Kingdom.